Stanford physician-scientist joins the Academy’s Class of 2026, bringing expertise in cardiovascular medicine, stem-cell ...
Dose escalation is ongoing in the OSPREY study, with the first two dose cohorts now complete and the third cohort expected to ...
Second of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion of the Final Clinical ...
The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor ...
These new findings add to the clinical evidence supporting obexelimab’s investigational role as a reversible, steroid-sparing ...
Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S. WAYNE, Pa., ...
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal ...
Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic ...
Starting next year, GSK plans to demolish existing buildings and construct new facilities to support clinical and commercial ...
Late-breaking oral presentation at Retina Subspecialty Day outlines data from Beacon’s pivotal VISTA trial, which met its FDA ...
Compared with standard povidone-iodine (PVP-I), I2Pure's formulations exhibited minimal residual staining and were readily ...
Pre-screening is now underway to enroll the single patient in Cohort 2, who is expected to receive RC220 at 100 mg/m 2 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results